GRUPPO SORIN R&D

Projektträger – zwischengeschaltetes Finanzinstitut

SORIN SPA

Ort

• Frankreich
• Italien

Beschreibung

Financing of the Sorin Group research and development activities in the cardiac surgery and rhythm management fields, in Italy (80%) and France (20%).

Ziele

The project concerns the company's research and development (R&D) of various new products and product improvements in heart failure with a particular focus on i) cardiopulmonary, ii) cardiac rhythm management and iii) heart valves.

Kommentar(e)

The Risk Sharing Finance Facility (RSFF) is an innovative credit risk sharing scheme jointly set up by the European Commission and the European Investment Bank to improve access to debt financing for private companies or public institutions promoting activities with a higher financial risk profile in the fields of research, technological development, demonstration and innovation investments.

Sektor(en)

• Industrie

Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)

EUR 100 million

Gesamtkosten (voraussichtlicher Betrag)

EUR 212 million

Umweltaspekte

The project mainly concerns investments in R&D that are expected to be carried out in existing facilities without changing their already authorized scope and would therefore not require an EIA under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

Auftragsvergabe

The promoter is a private company not operating in the Utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement. However, the promoter’s procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank’s services will verify details during the project due diligence.

Projektstatus

Unterzeichnet - 6/05/2014